

news from biocrates

Quick links

- Treatment of NAFLD | A metabolomic perspective
- Metabolite of the month | Melatonin
- Quantitative metabolomics using urine samples | Application note

Treatment of non-alcoholic fatty liver disease (NAFLD) as a chemopreventive strategy for other chronic disease

A metabolomic perspective

NAFLD is a key player in other chronic diseases – both as a prevalent comorbidity and a contributing factor. Does this mean that treating NAFLD could prevent those conditions? Our latest article explores the use of personalized, metabolomics-based lifestyle interventions in NAFLD as a chemopreventive strategy for other diseases.

[Read article](#)

Metabolite of the month

Melatonin

In this section, our scientists look at one specific metabolite each month. Topics of discussion include the biosynthesis and degradation in a broader health context, and the effect of dysregulation. In this month's article, they took a closer look at Melatonin.

[Read article](#)

Quantitative metabolomics using urine samples

Application note

Having a longstanding history with urine metabolomics, biocrates developed an extension set for urine analysis with the MxP® Quant 500 and AbsoluteIDQ® p180 kits. The performance results with three different mass spectrometer platforms are summarized in the following application note.

[Read application note](#)



LinkedIn



Twitter



Youtube



Email



Podcast